Brief: Regulus Announces Positive Data From The Second Cohort In Phase 1B Clinical Trial Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Regulus Therapeutics

12/03/2024 10:53

March 12 (Reuters) - Regulus Therapeutics Inc  RGLS.O :
    * REGULUS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE DATA FROM
THE
SECOND COHORT OF PATIENTS IN ITS PHASE 1B MULTIPLE-ASCENDING
DOSE (MAD) CLINICAL TRIAL OF RGLS8429 FOR THE TREATMENT OF
AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
    * REGULUS THERAPEUTICS INC - MECHANISTIC DOSE RESPONSE
OBSERVED AT
A 2MG/KG DOSE LEVEL BASED ON URINARY BIOMARKER ANALYSES
    * REGULUS THERAPEUTICS INC: COHORT 3 FULLY ENROLLED WITH
DATA
READOUT ANTICIPATED IN MID-2024; COHORT 4 SCREENING TO START IN
2Q 2024
    * REGULUS THERAPEUTICS INC: RGLS8429 WAS WELL TOLERATED WITH
NO
SAFETY FINDINGS OF CONCERN

Source text for Eikon:  ID:nPnJmySLa 
Further company coverage:  RGLS.O 

 ((Reuters.Briefs@thomsonreuters.com;))